Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Glioblastoma 4Glioma 3Neoplasms 2Multiple Myeloma 2Lymphoma 2Astrocytoma 2Whooping Cough 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumococcal Infections 1Papillomavirus Infections 1Pancreatic Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Medulloblastoma 1Measles 1Lymphoma, Non-Hodgkin 1Lipodystrophy, Congenital Generalized 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Human Papillomavirus-Related Cervical Carcinoma 1Hodgkin Disease 1Hepatitis B 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Tetanus Toxoid × Clear all
NCT03251924 2023-02-28

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Terminated
80 enrolled 33 charts
Tumor-Agnostic

Neoplasms

NCT00000105 2017-11-29

Vaccination With Tetanus and KLH to Assess Immune Responses.

Masonic Cancer Center, University of Minnesota

Terminated
112 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡